39627-98-0

Basic information

• Product Name: N-(2,6-Dimethylphenyl)-2-picolinamide
• Synonyms: N-(2,6-Dimethylphenyl)-2-Picolinamide;N-(2',6'-Dimethylphenl)-2-pyridinecarboxamide;N-(2,6-Dimethylphenyl)-2-Picolinamid;N-(2,6-Dimethylphenyl)pyridine-2-carboxamide;N-(2',6'-Dimethylphenyl)-2-pyridine carboxamide;N-(2,6-DIMETHYLPHENYL)-PICOLINAMIDE;2',6'-Picolinoxylidide;6'-DiMethylphenl)-2-pyridine carboxaMide
• CAS NO: 39627-98-0
• Molecular Formula: C₁₄H₁₄N₂O
• Molecular Weight: 226.27376
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 39627-98-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 104 °C(Solv: ethanol (64-17-5))
• Boiling Point: 290.3 °C at 760 mmHg
• Flash Point: 129.4 °C
• Appearance: /
• Density: 1.165 g/cm³
• Vapor Pressure: 0.00209mmHg at 25°C
• Refractive Index: 1.624
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 11.92±0.70(Predicted)
• CAS DataBase Reference: N-(2,6-Dimethylphenyl)-2-picolinamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,6-Dimethylphenyl)-2-picolinamide(39627-98-0)
• EPA Substance Registry System: N-(2,6-Dimethylphenyl)-2-picolinamide(39627-98-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 39627-98-0(Hazardous Substances Data)

Usage

Uses

Bupivacaine impurity.

InChI:InChI=1/C14H14N2O/c1-10-6-5-7-11(2)13(10)16-14(17)12-8-3-4-9-15-12/h3-9H,1-2H3,(H,16,17)

Upstream product

• 98-98-6 2-Picolinic acid 
• 541-41-3 chloroformic acid ethyl ester 
• 83441-22-9 Pyridine-2-carbothioic acid (2,6-dimethyl-phenyl)-amide 
• 29745-44-6 pyridine-2-carbonyl chloride 
• 87-62-7 2,6-dimethylaniline 
• 109-04-6 2-bromo-pyridine 
• 201230-82-2 carbon monoxide 
• 636-80-6 2-picolinic acid hydrochloride 
• 882994-68-5 2,6-dimethyl-N-((pyridin-2-yl)methyl)benzenamine 
• 6959-47-3 2-chloromethylpyridine hydrochloride 

Downstream Products

• 111562-44-8 2-(2,6-dimethyl-phenylcarbamoyl)-1-methyl-pyridinium; iodide 
• 15883-20-2 2',6'-pipecoloxylidide 
• 83441-22-9 Pyridine-2-carbothioic acid (2,6-dimethyl-phenyl)-amide 
• 96-88-8 mepivacaine 
• 78289-28-8 pipecolic-2-acid-2',6'-xylidide 
• 98626-61-0 1-propyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide 
• 14252-80-3 racemic bupivacaine 

Relevant articles and documents

HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE

Provided are a heterocyclic carboxylic acid amide ligand and applications thereof in a copper catalyzed coupling reaction. Specifically, provided are uses of a compound represented by formula (I), definitions of radical groups being described in the specifications. The compound represented by formula (I) can be used as the ligand in the copper catalyzed coupling reaction of the aryl halogeno substitute, and is used or catalyzing the coupling reaction for forming the aryl halogeno substitute having C—N, C—O, C—S and other bonds.

Synthesis of Mepivacaine and Its Analogues by a Continuous-Flow Tandem Hydrogenation/Reductive Amination Strategy

Herein we report a convenient, fast, and high-yielding method for the generation of the racemic amide anaesthetics mepivacaine, ropivacaine, and bupivacaine. Coupling of α-picolinic acid and 2,6-xylidine under sealed-vessel microwave conditions generates the intermediate amide after a reaction time of only 5 min at 150 °C. Subsequent reaction in a continuous-flow high-pressure hydrogenator (H-Cube ProTM) in the presence of the respective aldehyde directly converts the intermediate to the final amide anaesthetics in a continuous, integrated, multi-step ring-hydrogenation/reductive amination protocol. Merits and limitations of the protocol are discussed.

Topalgia treatment methods and compositions for treating

The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for the treatment of local pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of infiltration, nerve block, epidural, intrathecal anesthesia, pain, severe pain, chronic pain, chemotherapy induced pain, neuropathic pain, post herpetic neuralgia, neuralgia, motor neurone disease, diabetic neuropathy, postheipetic neuralgia, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, cancer pain and Sower back pain.